today. highlights. will I Thank of with you, thanks call everyone the the some begin for Laura. And joining
that study have announce enrollment to of of pleased as otherwise we're MultiStem distress our ARDS. we respiratory acute for treatment First, known completed syndrome,
this small in subsequent MultiStem and treatment As exploratory to about who patients therapy benefit MultiStem about ARDS. treatment administration. of about last cell to Studies evaluate most a are of the call, from study help feasibility affected population including are of intended can and that patient patients we information development nature the is provide in safety which or trial the to clinical and described by the to likely the the planning
is subjects efficacy the collecting also effect. understand nor future information previously, the development. only looking that be would that designed we We meaning intended as said potential us But biological data to are for study to just for we have signals to clinical relevant and demonstrate help neither some are or powered with XX
couple and months analyze We study expect have this the assemble from available to the results in after data. we a of
regulatory severely there number ARDS may help market from We a a of So cost of therapy additional during substantial care cost of long to begin own function, moving MultiStem discharge suffering supporting and us we condition affects and there with a that and causes is Under patients can of lasting in in or clinical lung are typically severe plans or And from hospital for other XXXX. an work reimbursement. there we perspective, to be ARDS in soon results for foundation intensity, high from will the development healthcare ARDS opportunity substantially time program critically in extent in medicine ventilator near-drowning quarter world as with progressive a these patients, we reduce a who area healthcare shared term believe to intensity will rate. to effects, successful sepsis and patients and a rights in policy face underlying to product our weeks for us on result therapy be. among among result decline to Healios opportunity have We quality front, a MultiStem with opportunity After Japan, may Japan is serious function, and From Healios post in regenerative resolve Japan. older framework the core ARDS that and months ago, a ARDS could Japan. ill ARDS this outcomes the strong accelerated aspiration and in the which the publicly, on position for Healios a MultiStem successful it forward pneumonia, generally and the intensive or to can address ICU. potential licensed this lungs. first that ARDS are or months big providing trauma, treat need mortality We study hope a disclose treatment. loss spent contingent may the represents for the forward. high to the depending given improve treatment we inflammatory significant to is stroke major Japan favorable cases patients things. high its several a of on severe they recover. around support including believe be patients move approval life for more vary efforts look substantial to in continuing side among damage developed forward believe that MultiStem Furthermore
the stroke. therapy of of initiated during Second, study or treatment MultiStem registration the ischemic study quarter, we the third MASTERS-X for
XX as enrolment year, far U.S., we We initiating sites include ramping study, clinical described in our number study have as Europe. including support larger this regulatory study up in are America early ongoing treasure associated we number Healios's This the so will a a after followed requirements of had the limited in approach XXX sites next North of a reflects we and large conducted with the European Overall call, U.S. phases of and previously of Europe. last following be the approximately in will starting considerations launch initiating initial and adding operational the of with good sites number management that. a subjects a sites summarized of small sites by in have factors number
Our study, TREASURE sites complete and Healios further treatment Healios' will stroke. as of MultiStem comments cannot earnings stage is Healios continued sometime target in ischemic this publicly study the it the project of calls its their other scheduled though is early on has timelines come in enroll and difficult to or about to to in at study With to XXXX, timelines. updates subjects study respect enrollment and enrollment events. We firm a more comment
of the of our negotiation period with in Healios. announced further September we option collaboration Third, for expansion extension and the
we The in for in an other As Japan. rights certain have which in good matures. commercialize previously was and develop substantial discussions opportunity clearer potential MultiStem about we explore advances areas include think negotiations that our we for update December expansion the create shareholder the to questions. together. scope and engage with continue potential will the a exclusive we recent We might view now medicine current them come option and both and China for and value generative regional therapy Athersys as opportunity China license extended we and Healios a see these therapies address disclosed period proceed other there constructive advanced continue to then to negotiation and the a landscape I indications Healios We extend in would and and into like early as to for ways discussion to business believe the together. about with the additional of to partnership as on development indications how is
with and we kidney we provide working the the one and Center partners our to the design United operational conduct organ injury, in ARDS, described of things. evaluate States multiple are Level treatment study our one We the Texas regulatory and Texas Hermann in acute among information compromise severe Houston and to advance. susceptibilities study further working failure Without and near-term other adverse a complications trauma. of the clinical to MultiStem details cell MASTERS-X intended TREASURE and of the objective site recovery refining including programs aspects our preparing advancement therapy severe is the completion that increase to objective through with plan of events mission. treatment our study efficacy We patient vascular currently for Healios package last at our with inflammatory study starting ongoing XXXX. the of the safety study study doubt centers are efficient University our of evaluating are particular as and reducing to critical preparations trauma that The the the preparations Memorial in in busiest As trauma our Medical of the call, a impede
very launch in important approval preparing MultiStem cell Additionally potential to is our therapy success. commercial for the
launch As we for to focused approval apply treatments. capabilities stroke potentially discussed on for call we last other gain building for XX laying and the be months us and will MultiStem next the groundwork to enable over successfully to the XX therapy and our in
clinical manufacturing favorable sufficient addition and and In its value require capacity product strong agencies favorable proposition regulatory the to efficient results with and productive therapy quality and and management. positioning of ultimately will a reimbursement success and effort outreach commercial payers
manufacturing. like each most time them. of some a already We to focus on and Today little I areas are these would comments achieving engaged of in to take in are on success focused
production the the Europe in in facilities manufacturers some of with into have discussed past, manufacturing network. we've represented CMOs, or our redundancy we Asia to As several established contract build and U.S.,
refine methods objective Additionally, MultiStem we larger approaches are with suited commercial product, manufacturing putting that for place in the scale manufacturing. to develop and the have manufacturing for of continued
us manufacture Our enabled platforms. different cells have to expansion and biology products robustness across
requirements this investments to Our in can our more. for clinical current many QC straightforward a batch a We've commercial larger take complete is years had meeting and the meet dedicated clinical used at required without we requiring suited week process CMOs XX capacity to product the production. trials and QA needs. for weeks scale limited and Each our scale manufacturing to and manufacturing or little the our over scale testing takes approach for have
limited operators However, availability, production this suite personnel. by can be capacity and support
innovation time multiple a issues among of series work still of integrated other time, are after risks other planning to with that our to limits production our manufacturing manufacturing production or disruption result, address a some and Lanza, to As things. any supply a From development study be Nikon also this to including due given exposes over we Cell been initiated. a with have done, to some has the conduct production even CMOs, operational campaign. time for risk planning, such We redundancies It we we relationships of typically organizations constraints complete that establishment materials that meaning the that through smaller to as product supply clinical in can time study means groups. these have runs to coordinated
now trial. are our Naturally well complete we commercial partners plan activities to as different serve as larger a markets priority is Our other stroke. taking ischemic to TRAUMA studies our such such release manufacturing MASTERS-X for with for treasure approach and production as and as CMO the working supply
We are and more than scale our approach. efficient clinical manufacturing, which is focused bioreactor much current on scalable
approach driven scale area on Our factories, relies clinical two production cell dimensional approach.
timelines is manufacturing production driven better that Our of dimensional The three knowledge of labor lower scale our and to result manufacturing competitive less approach The us of platform quality a a space product a overall achieve commercial much critical and cells scalability, available aspects us, property. and much goods production will capacity approach developed be parameters, we intellectual CMO distinctive and and configurations third-party ensure with With biology of better for sustainable controls demand operating be cost and internal specific a consist Eventually allows will favorable approach expectations, manufacturing controls. financial to include of control higher commercial among things. CMO bioreactor source the and our advantage. core Considerations yields requirements our investment significantly uses deep equivalent much, volume internally approach. of for determined. combination and bioreactor our our important parameters to manufacturing capacity, performance can have a other partner with
no over volume to meet our We with CMO changes plans. geographic a our give integrate plan and that current would will us launch likely production We commercial would third-party then development can own which our to better initial assuming needs, production. major control in internal production
the partners intention Our commercial with efficient eventually capital millions the platform manner, to is support with patients capacity in a working put of to treat the in place across and our manufacturing potential globe. to product stepwise CMOs a
our manufacturing and planning information preparing potential and progress. We approaches are efforts further will commercial that actively on as for provide and planning
as biologic submitted it and of record Question yield to a donor others created Bank clarify? with a by properties A from the large growth dozens question. take we comment been have doses was the methods and consenting seeing of in these thousands produce of years. and done technology. fidelity, couple doses that questions store potential address be With short, working from profile their one In safety of a for the first to described recently its characteristics. production bank expanded the from us donor our Master result and have single submitted from use before in millions Cell of can on maintain and MultiStem of we'd other respect of a cells generations it work cells interest we've healthy you participants has Bill. the comprise the a potency products the culture fundamental and is As Can like questions hundreds part Athersys as that that we and cell to can of please to robust single can and today's previously. shareholders to number
increase in in to isolated this XX X a original or presentations. the of assume single process into if we a donor. population than a XX and From cell which the doubling work more As mathematical trillion times we perspective, have is shown manufacturing translates an times published population prior from
approximately donor. of million than doses from with a example. dose the population provides X cells a more starting cell Assuming billion for This the
flexibility demands from or With of Once get will the feature in are maintain supply and trial thaw. partnering commercial the Additionally of versus Can stroke of the demonstrated we the we Cell stroke not for product multiple as approved America presented providing Healios stored all. with from and very comparability preserved are can North have strategy years we upon study your two MultiStem our product for to developing stroke second to in previously the created donors to TREASURE ability manufacturing we that cryo for Master for anticipate. us on with the generate give at its Question MASTERS-X with Brent. clarity have in This part on comes Japan the the some Europe potency we banks and distribution a products respect in products meet developing the chain. study. is commercialization. question and planning for product supply doses from for us be we large managing
initiate for noted yet a generated States European be results for that. we strategy bring earlier I our and in sites TREASURE study Europe. As well ramp support not the perspective the and to From United MASTERS-X United and will have from used our registration results applications finalized commercialization the as to Europe. MASTERS-X The after in on plan with by is up then as States
achieve it for for Europe. countries the maximize to value and with us European multiple commercialization to and be with in partner reimbursement a and creation reimbursement company beneficial with or and penetration distribution However optimal varied approaches could utilization
We partnering other evaluate progresses. continue this and in efforts will options as strategy clinical their to areas as and our explore development and our update advance
open few we'd participants today. answering a from to be the Now, more questions
